Af­ter two pa­tient deaths from pre­sumed sep­sis, FDA puts par­tial hold on Zen­tal­is stud­ies

The FDA put three clin­i­cal stud­ies of Zen­tal­is’ WEE1 in­hibitor on par­tial hold fol­low­ing two pa­tient deaths like­ly from sep­sis in one study ear­li­er this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.